Regarding CDK4/6- and MEK-ERK-targeted treatment regimens, a phase I/II trial is currently investigating the ERK inhibitor ulixertinib in combination with palbociclib in different tumor entities, including metastatic pancreatic cancer and melanoma based on promising preclinical data (Goodwin et al. 2023); however, this trial does not require any specific mutational profile in the pancreatic cancer expansion cohort (NCT03454035). The gene discussed is CDK4; the disease is pancreatic neoplasm.